Manufacturers report baricitinib improved pain, physical function and morning joint stiffness in rheumatoid arthritis in post-hoc analyses of RA-BEAM phase 3 study

In the post-hoc analysis of this study, patients treated with baricitinib 4 mg saw numerical improvements in pain relief and a reduced duration of morning joint stiffness, at 12 weeks vs adalimumab and placebo.

Source:

Biospace Inc.